Meanwhile, Biopartners is fuming over the EMEA’s rejection of Biferonex, its Avoxex/Rebif knockoff: <a href="http://finance.yahoo.com/news/Biopartners-to-Appeal-the-bw-14418479.html" target="_blank">http://finance.yahoo.com/news/Biopartners-to-Appeal-the-bw-14418479.html</a>